A 35-year follow-up of a large cohort of patients with primary biliary cirrhosis seen at a single centre

Liver International

Volumn 31, Issue 3, 2011, Pages 361-368

  Floreani, Annarosa ^a   Caroli, Diego ^a   Variola, Angela ^a   Rizzotto, Erik Rosa ^a   Antoniazzi, Sara ^a   Chiaramonte, Maria ^b   Cazzagon, Nora ^a   Brombin, Chiara ^a   Salmaso, Luigi ^a   Baldo, Vincenzo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

Author keywords

Mortality; Primary biliary cirrhosis; Survival; Ursodeoxycholic acid

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; MITOCHONDRION ANTIBODY; PENICILLAMINE; PREDNISOLONE; SERUM ALBUMIN; URSODEOXYCHOLIC ACID;

ADULT; AGED; ARTICLE; ASCITES; ASYMPTOMATIC DISEASE; BACTERIAL PERITONITIS; BLEEDING; BRAIN DISEASE; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIMARY BILIARY CIRRHOSIS; PROGNOSIS; PROSPECTIVE STUDY; PROTHROMBIN TIME; SURVIVAL; TREATMENT DURATION;

CAUSE OF DEATH; CHOLAGOGUES AND CHOLERETICS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; ITALY; LIVER CIRRHOSIS, BILIARY; LIVER FAILURE; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 79551523758     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02366.x     Document Type: Article

References (30)

1. Mahl R, Shockcor W, Boyer JL. Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. J Hepatol 1994; 20: 707-13.
2. Springer J, Cauch-Dudek K, O'Rourke K, Wanless IR, Heathcote J. Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis. Am J Gastroenterol 1999; 94: 47-53.
3. Mitchison HC, Lucery MR, Kelly PJ, et al. Symptoms development and prognosis in primary biliary cirrhosis: a study in two centers. Gastroenterology 1990; 99: 778-84.
4. Gores GJ, Wiesner RH, Dickson ER, et al. Prospective evaluation of esophageal varices in primary biliary cirrhosis: development, natural history and influence on survival. Gastroenterology 1989; 96: 1552-9.
5. Prince M, Chetwynd A, Newman W, Metcalf JV, James OF. Survival and symptom progression of a geographically based cohort of patients with primary biliary cirrhosis: follow-up to 28 years. Gastroenterology 2002; 123: 1044-51.
6. Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology 2009; 50: 291-308.
7. Corpechot C, Carrat F, Bahr A, et al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005; 128: 297-303.
8. ter Borg PC, Schalm SW, Hansen BE, van Buuren HR, the Dutch PBC study group. Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol 2006; 101: 2044-50.
9. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006; 130: 715-20.
10. Gong Y, Huangh Z, Christensen E, Gluud C. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am J Gastroenterol 2007; 102: 1799-807.
11. Jackson H, Solaymani-Dodaran M, Card TR, et al. Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study. Hepatology 2007; 46: 1131-7.
12. Scheuer JJ. Primary biliary cirrhosis. Proc R Soc Med 1967; 60: 1257-60.
13. Chazouilleres O, Wendum D, Serfaty L, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998; 28: 290-301.
14. Cavazza A, Caballeria L, Floreani A, et al. Incidence, risk factors, and survival in hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers. Hepatology 2009; 50: 1162-8.
15. Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A. Prognosis in primary biliary cirrhosis: a model for decision making. Hepatology 1989; 10: 1-7.
16. Conn HO, Leevy CM, Vlahcevic ZR, et al. Comparison of lactulose and neomycin in treatment of chronic portal-systemic encephalopathy - double blind controller trial. Gastroenterology 1977; 72: 573-8.
17. Rautiainen H, Salomaa V, Niemela S, et al. Prevalence and incidence of primary biliary cirrhosis are increasing in Finland. Scand J Gastroenterol 2007; 42: 1347-53.
18. Prince MI, Chetwynd A, Craig WL, Metcalf V, James OF. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. Gut 2004; 53: 865-70.
19. Kumagi T, Onji M. Presentation and diagnosis of primary biliary cirrhosis in the 21st century. Clin Liver Dis 2008; 12: 243-59.
20. Prince MI, Chetwynd A, Diggle P, et al. The geographical distribution of primary biliary cirrhosis in a well-defined cohort. Hepatology 2001; 34: 1083-8.
21. Newton JL, Jones DE, Metcalf JV, et al. Presentation and mortality of primary biliary cirrhosis in older age. Age Ageing 2000; 29: 305-9.
22. Chan CW, Tsochatzis EA, Carpenter JR, et al. Predicting the advent of ascites and other complications in primary biliary cirrhosis: a staged model approach. Aliment Pharmacol Ther 2010; 298: C486-95.
23. Floreani A, Baragiotta A, Baldo V, et al. Hepatic and extra-hepatic malignancies in primary biliary cirrhosis. Hepatology 1999; 29: 1425-8.
24. Su C-W, Hung H-H, Huo T-I, et al. Natural history and prognostic factors of primary biliary cirrhosis in Taiwan: a follow-up study up to 18 years. Liver Int 2008; 28: 1305-13.
25. Christensen E. Prognostic models including the Child-Pugh, MELD and Mayo risk scores - Where are we and where should we go? J Hepatol 2004; 41: 344-50.
26. Gong Y, Huang ZB, Chriostensen E, Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2008; CD000551.
27. Corpechot C, Carrat F, Bonnand AM, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000; 32: 1196-9.
28. Lindor KD, Jorgensen RA, Therneau TM, Malinchoch M, Dickson ER. Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. Mayo Clin Proc 1997; 72: 1137-40.
29. Mendes FD, Kim WR, Pedersen R, Therneau T, Lindor KD. Mortality attributable to cholestatic liver disease in the United States. Hepatology 2008; 47: 1241-7.
30. Kuiper EMM, Hansen BE, De Vries RA, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009; 136: 1281-7.